



December 02nd 2022

Temporary Shortage of Sabril® (Vigabatrin) 500mg Film Coated Tablets (PA 540/23/001)

Dear Healthcare Professional,

Sanofi are writing to inform you of a supply shortage of:

*Sabril 500 mg film-coated tablets PA 540/23/001 (Vigabatrin).
This product will be out from stock from 19th December until 02nd January 2023*

Firstly, we apologise for the inconvenience and difficulty for you and your patients that this supply shortage may cause. We are using our best efforts to minimise the duration of this shortage which is due to a delay in supply of vigabatrin active substance from our current supplier.

Updated information on the return to supply will be available on the shortages section of the HPRA website.

1. Patients being treated with Sabril 500 mg film-coated tablets who cannot be supplied with this product should urgently be referred to their Health Care Professional.

According to the clinical situation of the patient and the availability of alternatives, a switch to another formulation of vigabatrin, or to an alternative therapy, should be decided by the patients' Health Care Professional, according to the individual needs of the patient and in compliance with the national guidelines.

Sabril 500mg granules for oral solution (PA 540/23 /002) remain available and are not impacted by the current shortage.

2. Patients not currently being treated (initiation treatment):

Therapy should be decided by the patients' Health Care Professional, in accordance with the needs of the individual patient and depending on the availability of vigabatrin or alternative therapies.

MAT-IE-2200546 (V1.0)

December 2022

Further information

If you require any further information in relation to this, please contact:

Medical Information at Sanofi, 18 Riverwalk Citywest Business Campus Dublin 24

- Tel: + 353 1 403 5600.
- Email: IE-Medicalinformation@sanofi.com

For questions relating to ordering, please contact:
Sanofi Customer Services – +353(0)14035600 (Mon-Fri 9am – 5pm).

Sanofi apologies for any inconvenience that this medicine shortage may cause you or your patients.

Yours Sincerely,



Deborah Woods
Head of Medical, General Medicines UK & Ireland